Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes
Authors
Keywords
-
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 25, Issue 8, Pages 2241-2248
Publisher
Springer Nature
Online
2018-05-22
DOI
10.1245/s10434-018-6531-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study
- (2016) Carlos A. Puig et al. ANNALS OF SURGICAL ONCOLOGY
- Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study
- (2016) Akiko Chiba et al. ANNALS OF SURGICAL ONCOLOGY
- A Phase II Study of Adjuvant Chemotherapy of Tegafur–Uracil for Patients with Breast Cancer with HER2-negative Pathologic Residual Invasive Disease After Neoadjuvant Chemotherapy
- (2016) SATORU TANAKA et al. ANTICANCER RESEARCH
- The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy
- (2016) Elizabeth A. Mittendorf et al. JAMA Oncology
- Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors
- (2015) Zahraa Al-Hilli et al. ANNALS OF SURGICAL ONCOLOGY
- Landscape of Neoadjuvant Therapy for Breast Cancer
- (2015) Tufia C. Haddad et al. ANNALS OF SURGICAL ONCOLOGY
- Neoadjuvant treatment of breast cancer – Clinical and research perspective
- (2015) Sibylle Loibl et al. BREAST
- Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States
- (2015) Sarah S. Mougalian et al. CANCER
- Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer
- (2014) Judy C. Boughey et al. ANNALS OF SURGERY
- Current and future role of neoadjuvant therapy for breast cancer
- (2014) Michael Untch et al. BREAST
- First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer
- (2014) L. Amiri-Kordestani et al. CLINICAL CANCER RESEARCH
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy
- (2014) Kunpeng Wu et al. World Journal of Surgical Oncology
- Individualizing breast cancer treatment—The dawn of personalized medicine
- (2013) Argha Nandy et al. EXPERIMENTAL CELL RESEARCH
- Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
- (2011) Matthew J. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
- Using the NCDB for cancer care improvement: An introduction to available quality assessment tools
- (2009) Mehul V. Raval et al. JOURNAL OF SURGICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now